1st EUROPEAN BRAIN POLICY FORUM
A FOCUS ON PARKINSON’S DISEASE AND THE EUROPEAN SOCIETY

BRUSSELS BELGIUM
February 27-28 2008

FINAL PROGRAMME

www.kenes.com/ebpf2008

Endorsed by the
The Movement Disorder Society
1st EUROPEAN BRAIN POLICY FORUM

A FOCUS ON PARKINSON'S DISEASE AND THE EUROPEAN SOCIETY

February 27-28, 2008

BRUSSELS
BELGIUM

FINAL PROGRAMME
CONTENTS

Welcome ................................................................................................................ 3

About the European Brain Council ............................................................... 4

Acknowledgments ................................................................................................... 5

General Information .............................................................................................. 6

Refreshments ............................................................................................................ 6

Programme ............................................................................................................... 8

Speakers .................................................................................................................. 11
Dear Guest,

The EBC Board and the Congress Committee join us in welcoming you to Brussels and to this very special event.

We thank you for taking the time to be with us and for sharing your expertise and experience with the other ‘stakeholders’ who are extremely interested in the topic of the “Brain” and Parkinson’s Disease in particular.

We look forward to a most interesting and successful conference, in which your contribution will be invaluable.

With best wishes,

Jes Olesen
President

Mary G. Baker, MBE
Vice President
ABOUT THE EUROPEAN BRAIN COUNCIL

EUROPEAN BRAIN COUNCIL

The European Brain Council (EBC) is a co-ordinating council formed by pan-European organisations in neurology, neurosurgery, psychiatry, neuro-psychopharmacology, basic brain research (neuroscience), as well as patient advocacy federations and industry. It therefore represents a vast network of patients, doctors and scientists, and these stakeholders - along with the industrial partners - make EBC eminently suited to work in close partnership with the European Union commissions, the European Parliament and the World Health Organisation (WHO), as well as other decision-making bodies. The EBC was formally established in Brussels in 2002, and has offices in Brussels and Florence.

EBPF Forums

Beginning with this conference in 2008, the EBC is launching a series of Annual Multidisciplinary Forums to involve all stakeholders in brain research. These events, with their format of short presentations followed by moderated debate, are intended to contribute an informed and expert overview for the building of a European research strategy which will be more effective in tackling the major brain diseases.

Each forum will focus on one major disease - in particular, neglected areas of that disease – and the first will be devoted to “Parkinson’s disease and the European society”. The goal of each event will be to highlight the imbalance between, on one hand, the scale of the effect of the illness on people affected (and society in general) and, on the other hand, the level of resources allocated to deal with the problem. This relates particularly to research and resource requirements for making further progress in understanding that disease.

The format of these meetings will reflect the broad constituency of the EBC by including politicians, patients, policy-makers, industry representatives, representatives of health policy think tanks and opinion leaders as well as the scientists and physicians who carry out the research. The hope is that those researchers will emerge from the forum newly motivated to work together towards a roadmap for improving treatment, and that other stakeholders should have had the opportunity to listen to and voice opinions on that roadmap, so that they will fully support it as it moves forward.

Each Forum will open with an analysis of the burden and cost of the disease in Europe, following on the recent studies carried out by the EBC and the Swedish company Stockholm Health Economics into the “Cost of Disorders of the Brain in Europe”, “Resource Allocation to Brain Research in Europe” and the “Consensus Document on European Brain Research”.

Jes Olesen,  
President, European Brain Council

Mary Baker, MBE  
Vice-President, European Brain Council
ACKNOWLEDGEMENTS

Endorsed by the

The Movement Disorder Society

We are most grateful for the contribution of:

[Logos of various organizations]

And

[Logos of additional organizations]
GENERAL INFORMATION

Venue
Sheraton Brussels Hotel
Place Rogier, 3
B-1210 Brussels
Belgium
Tel: +32 2 224 3111
Fax: +32 2 224 3456
www.sheraton.com/brussels

Language
The official language of the Forum is English.

Registration Desk
The Registration Desk will be operating during the following hours:
Wednesday, February 27, 2008   10:00 – 20:00
Thursday, February 28, 2008    08:00 – 14:00

Forum Kit and Name Badge
Upon registering you received your kit containing your personal name badge. Please remember to wear your name badge at all Forum activities to gain entry to the sessions.

Conference Meeting Room
The Conference Meeting Room “Salle des Nations” is located on the 2nd floor.
Wheelchair accessible toilets are located on the 30th Floor.

Attendance Certificates
An attendance certificate is located inside your participant kit.

Currency
The official currency of Belgium is the Euro.

Personal Insurance
We recommend that all participants take out a personal travel and health insurance for their trip.
1st European Brain Policy Forum Organizers
European Brain Council,
Evelyn Sipido
c/o University of Florence
Dept. of Pharmacology
Viale Pieraccini, 6
50139 Florence – Italy
Tel: +39-055-4362098
Fax: +39-055-4271 280
E-mail: evelyn.sipido@unifi.it
Website: www.europeanbraincouncil.org/ebpf2008

Kenes International – Global Congress Organizers and Association Management Services
1-3 Rue de Chantepoulet
PO Box 1726
CH-1211 Geneva 1
Switzerland
Tel: +41 22 908 0488
Fax: +41 22 732 2850
E-mail: ebc2008@kenes.com
Website: www.europeanbraincouncil.org/ebpf2008

REFRESHMENTS

Lunches
A light lunch will be served on Wednesday, February 27 and Thursday, February 28 in the foyer outside the session hall of the Sheraton Brussels Hotel.

Dinner & Drinks on Wednesday, February 27 at 19:30
All registered participants are invited to join us on the 30th floor of the Sheraton Hotel for dinner.

Coffee
Coffee will be served in the foyer outside the session hall at the times indicated in the Scientific Program.
## PROGRAMME

**WEDNESDAY, FEBRUARY 27, 2008**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>REGISTRATION OPENS</td>
</tr>
<tr>
<td>13:00</td>
<td>LIGHT LUNCH</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>OPENING ADDRESS</td>
</tr>
<tr>
<td></td>
<td>Martyn Lewis, Facilitator</td>
</tr>
<tr>
<td></td>
<td>Jes Olesen, President EBC</td>
</tr>
<tr>
<td></td>
<td>Janez Potočnik, EU Commissioner for Research</td>
</tr>
<tr>
<td>14:15 – 14:35</td>
<td>KEYNOTE ADDRESS</td>
</tr>
<tr>
<td></td>
<td>Cost And Burden of Parkinson’s Disease</td>
</tr>
<tr>
<td></td>
<td>Bengt Jönsson, EHE</td>
</tr>
<tr>
<td>14:35 – 16:10</td>
<td>PANEL DISCUSSION - THEME 1</td>
</tr>
<tr>
<td></td>
<td>The Understanding of Parkinson’s Disease and the Response by the Medical Profession</td>
</tr>
<tr>
<td></td>
<td>Parkinson’s Disease - From History to Treatment</td>
</tr>
<tr>
<td></td>
<td>Olivier Rascol, France</td>
</tr>
<tr>
<td></td>
<td>Diagnostics &amp; Sub-Classification</td>
</tr>
<tr>
<td></td>
<td>Werner Poewe, Austria</td>
</tr>
<tr>
<td></td>
<td>Understanding the Pathophysiology</td>
</tr>
<tr>
<td></td>
<td>Peter Brown, UK</td>
</tr>
<tr>
<td></td>
<td>Medical Treatment</td>
</tr>
<tr>
<td></td>
<td>Eduardo Tolosa, Spain</td>
</tr>
<tr>
<td></td>
<td>Neurosurgical Treatment</td>
</tr>
<tr>
<td></td>
<td>Pino Carbone, Italy</td>
</tr>
<tr>
<td></td>
<td>Accurate Diagnosis of PD</td>
</tr>
<tr>
<td></td>
<td>Emilio Moreno, Spain</td>
</tr>
<tr>
<td></td>
<td>MDS-Europe: A Strategy for Optimal Management of Parkinson’s Disease</td>
</tr>
<tr>
<td></td>
<td>Wolfgang Oertel, Germany</td>
</tr>
<tr>
<td>16:10 – 16:30</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>16:30 – 18:00</td>
<td>PANEL DISCUSSION - THEME 2</td>
</tr>
<tr>
<td></td>
<td>The Impact of Parkinson’s Disease on Society:</td>
</tr>
<tr>
<td></td>
<td>The Patient’s Journey</td>
</tr>
<tr>
<td></td>
<td>My Journey</td>
</tr>
<tr>
<td></td>
<td>Tom Isaacs, UK</td>
</tr>
<tr>
<td></td>
<td>One Person Ill – Ten People Affected</td>
</tr>
<tr>
<td></td>
<td>Suzanne Lindvall, Sweden</td>
</tr>
<tr>
<td></td>
<td>Parkinson’s Disease – A Body &amp; Soul Disease:</td>
</tr>
<tr>
<td></td>
<td>Mood Disorders in Parkinson’s Disease</td>
</tr>
<tr>
<td></td>
<td>Paolo Barone, Italy</td>
</tr>
<tr>
<td></td>
<td>Is There an Equal Standard of Care Throughout Europe?</td>
</tr>
<tr>
<td></td>
<td>Grzegorz Opala, Poland</td>
</tr>
<tr>
<td></td>
<td>The Importance of the Media</td>
</tr>
<tr>
<td></td>
<td>Thomas Stuttaford, UK</td>
</tr>
<tr>
<td></td>
<td>Ensure the Dialogue Between Science and Society</td>
</tr>
<tr>
<td></td>
<td>Mary G. Baker, MBE, UK</td>
</tr>
<tr>
<td></td>
<td>Debate moderated by Martyn Lewis</td>
</tr>
<tr>
<td>18:30 – 19:30</td>
<td>1st EBC RESEARCH LECTURE</td>
</tr>
<tr>
<td></td>
<td>Research &amp; Public Health</td>
</tr>
<tr>
<td></td>
<td>John Bowis, MEP</td>
</tr>
<tr>
<td>19:30</td>
<td>DRINKS AND DINNER</td>
</tr>
</tbody>
</table>
THURSDAY, FEBRUARY 28, 2008

08:30 – 08:40
OPENING

Martyn Lewis, Facilitator
Manuel Hallen, Germany
Tarun Dua, WHO

08.40 – 09.00
KEYNOTE ADDRESS

Neuronal Network Repair, Prevent Degeneration, Stem Cells & Innovative Treatments, Inter-Activeness of Neuroscience Aspects
Olle Lindvall, Sweden

09:00 – 10:30
PANEL DISCUSSION - THEME 3

The Future of Parkinson’s Disease - Research and Health Policy

The Need for Molecular Imaging Techniques in Neuropharmacology
David Brooks, UK

Extrapolating Deep Brain Stimulation: Insights from Parkinson’s Disease and Dystonia
Pierre Pollak, France

Understanding Neuronal Networks to Improve Deep Brain Stimulation
Andreas Engel, Germany

Genetic Clues to Parkinson’s Disease?
Thomas Gasser, Germany

Proposal for Most Urgent & Imminent Strategies by EBC
Monica Di Luca, Italy

Duodopa in the management of PD
Werner Cautreels, Belgium

Debate moderated by Martyn Lewis

10:30– 11:00
COFFEE BREAK

11:00-11:20
KEYNOTE ADDRESS

The Challenge of a Long-term Progressive Illness like Parkinson’s Disease on Health Services
Sir Michael Rawlins, NICE, UK

11:20-12:30
PANEL DISCUSSION

EBC Consensus Doc on Brain Research: From Parkinson’s Disease & Other Movement Disorders to Basal Ganglia Degeneration
Jes Olesen, Denmark
Sir Michael Rawlins, UK
Olle Lindvall, Sweden
Manuel Hallen, Germany
Carolin Miltenburger, Germany
Mary G. Baker, UK

Debate moderated by Martyn Lewis

12:30 – 13:00
THE WAY FORWARD

Mary G. Baker, UK
Jes Olesen, Denmark
David Vodusek, Slovenia
Martyn Lewis, UK

13:00 – 14:00
LIGHT LUNCH
SPEAKERS

Mary Baker, MBE

is Patron and Immediate Past President of the European Parkinson’s Disease Association (EPDA), a position she was elected to in 1992 when the EPDA was first formed. With a membership of 38 European Parkinson’s Patient Organisations, the EPDA is a non-profit making organisation dedicated to the promotion of the international understanding of PD. Mary retired as Chief Executive of the Parkinson’s Disease Society of the United Kingdom in 2001 where she had worked for 18 years, advocating the needs of people living with Parkinson’s and their families and developing methods of good practice. Mary is also President of the European Federation of Neurological Associations, Vice President of the European Brain Council, Consultant to the World Health Organisation (WHO) and Chair of the Working Group on Parkinson’s Disease formed by the WHO in May 1997. She is Director at Large for the World Stroke Association, former patient editor of the BMJ (now Chair of the BMJ Patient Advisory Group), member of the ABPI Code of Practice and has received an Honorary Doctorate from the University of Surrey in recognition of her work within the world of Parkinson’s disease. Mary has also received numerous awards in recognition of her work in the field of Neurology, and PD in particular, including the European Woman of Achievement Award 2000, and the Human Communication International Award 2001.

Paolo Barone, MD PhD

is presently professor of Neurology at the University of Naples, Italy. He is also Chief of the Movement Disorders Unit and director of the Laboratory of Pharmacology at the Department of Neurological Sciences of the University of Naples, Italy. Professor Barone earned his medical degree in 1980 and trained as a neurologist at the University of Naples; he pursued post-graduate medical education and completed his PhD at the National Institutes of Health (NIH, Bethesda). He has served as professor of Pharmacology at the University of Cagliari, Italy before returning to Naples in 1990. Professor Barone’s research interests include: neuropharmacology of the dopamine system; experimental models of Parkinson’s disease (PD), transduction of dopaminergic signals in animals models of PD, clinical neuropharmacology of movement disorders. He has lectured extensively on PD at international meetings in Europe and in United States. Professor Barone actively participates in medical societies including the Movement Disorders Society for whom he has served as a member of several committees.
John Bowis

Conservative Member of the European Parliament for London.

- EPP/ED Group Coordinator & Spokesman on Environment, Health and Food Safety Committee.
- Member of the Development Committee and Group Spokesman on Human Rights. Vice President of the EU/ACP Joint Parliamentary Assembly.
- Member of the EP Delegation for Palestine.

Since 1999

Conservative MEP for London and Rapporteur for the Parliament on Food Safety, Health and Enlargement, Professional Qualifications, Health and Poverty Reduction in Developing Countries, the European Centre for Disease Prevention & Control, Patient Mobility, Major and Neglected Diseases in Developing Countries and Mental Health.

1997-1999

International Policy Adviser to the World Health Organisation’s Collaborating Centre at the Institute of Psychiatry in London, supporting the UN’s Nations for Mental Health Campaign.

1987-1997

Member of Parliament for Battersea.

1989-93

Parliamentary Private Secretary at the Department of the Environment and the Welsh Office.

1993-96

Health & Social Services Minister at the Department of Health British Minister on the Council of Health Ministers and at Council of Europe.

1996-97

Minister for Transport in London and for Road Safety.

1993-97

Sponsor Minister for Derby, Leicester and Nottingham.

From 1982-1986 he served as Councillor on the Royal Borough of Kingston upon Thames, where he was Chairman of Education.

OBE 1981
Hon. Fellow, Royal College of Psychiatrists 2003.

Website: www.johnbowis.com
David Brooks

is Hartnett Professor of Neurology and Deputy Head of the Department of Clinical Neuroscience in the Division of Neuroscience, Faculty of Medicine, Imperial College, London. He is also Head of the Neurology Group at the Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, London. Additionally, he is Head of Neurology, Medical Diagnostics, GE Healthcare PLC. He is a member of the UK Medical Research Council Neuroscience and Mental Health Board, the Research Advisory Panel of the UK Parkinson's Disease Society (Chairman 1996-7), and UK Huntington's Disease Association. He is also on the German Dementia Network and Inserm Neuroscience Advisory Panels. He was Chairman of the Scientific Issues Committee of the Movement Disorder Society 1998-2002 and of the Council of Management of the UK Parkinson's Disease Society 1997-8, and the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Disease Research 2002-2006. He is on the Editorial Boards of the Journal of Neural Transmission, Synapse, Molecular Imaging and Biology, Neurotherapeutics and Current Trends in Neurology, and was on the editorial boards of the Journal of Neurology, Neurosurgery, and Psychiatry 1998-2004 and Movement Disorders 1994-1998. In 2001 he was elected a Fellow of the Academy of Medical Science, UK. In 2002 he was invited to give the Stan Fahn Lecture at the International Congress of Movement Disorders, Miami, in 2003 the George Cotzias Lecture in Madrid, in 2004 the Charles E Wilson Lecture, the Psychobiology Institute, Jerusalem March 2004, in 2005 the Kuhl-Lassen lecture at the Society of Nuclear Medicine, Toronto, and in 2006 the Sprague lecture at UC Irvine. His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer's and Parkinson's disease and their validation of biomarkers therapeutic trials. To date, he has published over 250 reports in peer reviewed journals, including Nature, and his research is currently supported by grants from the UK Medical Research Council, the Alzheimer's Research Trust, UK Parkinson's Disease Society, and industry.

Peter Brown

is the head of the Sobell Department of Motor Neuroscience and Movement Disorders at the Institute of Neurology, University College London. He graduated in medicine from Cambridge University in 1984 and qualified as a neurologist in 1994. Since then he has been directly or indirectly supported by the Medical Research Council. His research group’s principal focus is the investigation of how functional connectivity within and between the human cerebral cortex and basal ganglia influences movement and changes in disease, particularly Parkinson’s disease. His multidisciplinary group includes neurologists, physiologists, software engineers and mathematicians and collaborates closely with neurologists and neurosurgeons over much of Europe.
**Giuseppe Carbone**

qualified in medical studies at the University of Milan in . After working as an internist he entered the clinical group of Sandoz Italy as Project Leader of the Endocrinology section. In 1989 Medtronic started its business in Italy and Dr Carbone worked in its clinical department holding positions within the Neuromodulation sector as head of marketing and business development. In 1998 he started his international experience as head of the marketing department and business at the Medtronic Headquarters for Europe working in particular on the promotion of Deep Brain Stimulation (Activa Therapy) for the treatment of PD. In order to promote this therapy he worked closely with the medical community but also with patient organizations - European Parkinson’s Disease Association (EPDA), European Dystonia Federation (EDF) and European Federation of Neurological Associations (EFNA) - as well as with scientific societies such as the European Brain Council (EBC). In 2004, Dr Carbone returned to Italy and now is Business Director for the Neurological Division of Medtronic Italy. In 2005 he obtained a postgraduate diploma on “Leadership Capability” at Glasgow Caledonian University, Scotland.

**Werner Cautreels**

was born in 1952 in Antwerp, Belgium, and graduated from Antwerp University in chemistry, gaining a doctorate in analytical organic chemistry. He joined Solvay Pharmaceuticals in 1997 as Global Head of Research and Development and was appointed CEO of the same company in January 2005. Prior to joining Solvay he was employed by Sanofi, Sterling Winthrop and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. Werner Cautreels is a director of Innogenetics NV (Gent, Belgium) and of ArQule Inc. (Woburn, MA, USA)

**Monica Di Luca**

has been professor of Pharmacology at the University of Milano since 1999.

In 1986 she graduated in Pharmacology and medicinal Chemistry at the University of Milano, in 1992 she discussed her PhD thesis at the University of Milano, and in 1993 she completed a PhD programme in the laboratory of Molecular Biology of the University of Utrecht, The Netherlands. Her primary research interest in related to brain and synaptic plasticity both in physiological and pathological conditions, with the primary aim to apply her basic findings to the cure of neurodegenerative diseases. She is author of more that 90 scientific publications on peer reviewed journals. Monica Di Luca is member of Council and Executive committee of several national and international scientific organization. From 2000 to 2006 she performed as secretary general of Federation of European Neuroscience Societies and form 2205 she is Chair of the Western Europe Chapter of IBRO.
Having worked as staff scientist at the Max Planck Institute for Brain Research (Frankfurt) between 1987 and 1995, Andreas Engel has developed a long-standing interest in the dynamics of distributed sensory representations, intermodal and sensorimotor integration, and in computational theories of perception and representation. He has been involved in major studies of neuronal synchronization in the visual system, of the functional role of temporally coherent activity and of the mechanisms leading to the establishment of coherent sensory object representations. In 1996, Dr. Engel established an independent research group at the Max Planck Institute for Brain Research, funded by the Heisenberg Program of the German Research Foundation. In 2000, he moved to the Research Center Jülich to set up the newly established Cellular Neurobiology Group at the Institute for Medicine. In 2002, he was appointed to the Chair of Neurophysiology at the University Medical Center Hamburg. Dr. Engel’s group has extensive experience with in-vivo multielectrode recording from humans, carnivores and rodents, as well as with EEG and MEG recordings in human subjects. The group is currently interested in the role of synchrony for sensorimotor transformations, in functional links between synchrony and perceptual states, and in the pathophysiological relevance of synchronization phenomena. In recent years, the group has studied the role of coherent neural activity quite extensively in human subjects using EEG, MEG and invasive microelectrode recordings in patients with neurological disorders undergoing stereotaxic neurosurgery for deep brain stimulation.

Tarun Dua

is working as a Medical Officer in the Department of Mental Health and Substance Abuse at World Health Organization, Geneva. She is a paediatric neurologist by training and has about 10 years of experience in clinical, research and public health aspects of neurology at national and international levels. She also has a Masters degree in public health with specialisation in health services management. She was involved in production of three major WHO documents - Atlas: Country resources for neurological disorders; Atlas: Epilepsy care in the world; and Neurological disorders: public health challenges. She is the focal point in WHO for the area of neurological disorders, including management of neuropsychiatric and developmental problems in children. She coordinates the various Global Campaigns for neurological disorders such as on epilepsy and headache disorders and is involved with the revision of global burden of disease project. She has authored more than 50 publications.
Thomas Gasser

studied medicine at the University of Freiburg, Germany, and at Yale University Medical School, New Haven Connecticut. He received his professional training in psychiatry at the Max Planck-Institute of Psychiatry in Munich and in Neurology at the Department of Neurology of the Ludwig-Maximilians University in Munich. From 1991 to 1993 he trained as a Post-doctoral fellow with a stipend of the German Research Foundation at the Neuroscience Center, Massachusetts General Hospital and Harvard Medical School, in Boston in the laboratory of Prof. Xandra Breakefield. He returned to Munich to become assistant professor in Neurology and head of the Neurogenetics Unit as well as the Movement Disorders Outpatient Unit at the Department of Neurology of Munich University. In 2002, he became head of the Department of Neurodegenerative Diseases of the Hertie-Institute of Clinical Brain Research at the University of Tübingen. His main areas of research are the genetic and molecular basis of Parkinson’s disease and other movement disorders, as well as their diagnosis and treatment.

Manuel Hallen

Manuel Hallen, MD, born on 5 July 1949 in Heidelberg (Germany), studied medicine at the Universities of Lausanne (Switzerland) and Heidelberg. He worked with the Australian Royal Flying Doctor Service (Western Australia) in 1977, and afterwards at the Department of Internal Medicine, Klinikum Mannheim of the University of Heidelberg (cardiology, intensive care). In 1984 he became Deputy Scientific Director at Staticon Research Institute for Biostatistics and Clinical Research, a contract research organisation in Munich (Germany).

In 1990 he joined the European Commission, Directorate General for Research in Brussels (Belgium) in the Medical Research Programme, where he was in charge of epidemiological research. From 1993 to 1998 he was responsible for human genome research in the EC Framework Programmes until he was appointed Head of Unit in 1999 in the “Quality of Life programme (FP5)” for the area “Generic RTD Activities and Infrastructures” which covered mainly genomics, biomedical research, neurosciences, and public health research. In 2002 he has taken over a Unit dedicated to “Fundamental Genomics” within the Life Sciences, Genomics and Biotechnology for Health programme (FP6), and since May 2004 he is Head of Unit on “Policy and Strategy” in the area Biotechnology, Agriculture and Food (FP6).
Tom Isaacs

was diagnosed with Parkinson’s at the young age of 27 and since then, has done everything he can to fight the condition, raise funds and heighten awareness. Having completed a 1,250 mile walk from John O’Groats to Lands End and raising £40,000, in 2002 Tom left his job as director of a London property company to undertake his Coastin’ challenge beginning in April of that year. By April 2003, Tom had walked 4,500 miles around the British coastline, climbed the highest mountains in England, Scotland and Wales and ran in the Flora London Marathon, raising over £350,000. In 2004 he was runner up in the GMTV/Daily Mirror Fundraiser of the Year Award and in 2005 he was elected Charity Personality of the Year. He is Co-Founder and Managing Director of The Cure Parkinson’s Trust, formed in 2005. Since its inception, the Trust has allocated significant funds to research and believes it is making huge strides towards its goal. He is also the Young Onset Representative on the Board of the European Parkinson’s Disease Association. Tom has recently written a book “Shake Well Before Use” about his walk and his experiences with Parkinson’s and presents regularly about his condition both in the Parkinson’s community and more widely; always emphasising his own perspective as a patient.

Bengt Jönsson

is Professor of Health Economics at the Stockholm School of Economics, Sweden since 1990. Before that he was professor at Linköping University, Department of Health and Society, 1982-1990. He was director of the Swedish Institute for Health Economics (IHE) from 1979 to 1982, and a member of the IHE Board until 2004. He is also a member of the Karolinska University Hospital Board, and the Scientific Advisory Board, National Board of Health and Welfare, Sweden. He was also Chair of the Expert Group to the Committee on Funding and Organisation of Health Services and Medical Care in Sweden (HSU 2000), and a member of the National Social Insurance Board from 1992 to 1994, and of SBU (The Swedish Council on Technology Assessment in Health Care), Scientific Advisory Board 1988-2004. Professor Jönsson is a member of the editorial boards of several journals, including the Journal of Health Economics, European Journal of Health Economics, Research in Health Care Financial Management, and PharmacoEconomics. He has also been a temporary adviser to the WHO and a consultant to OECD and UNIDO. Professor Jönsson’s extensive publications in the field of health economics include over 200 papers, reports, and book chapters. 2004-05 he was president of iHEA, the international Health Economists Association.
Martyn Lewis

Chairman & Co-Founder of Teliris - Chairman, NICE TV - Chairman and Founder of YouthNet UK

Chairman, The Beacon Fellowship Trust - Former TV reporter and news anchor

Over 32 years as a TV journalist, Martyn Lewis built up a reputation as one of Britain’s best known TV anchormen and reporters, before taking up a business career. He continues to chair numerous conferences and debates in the government, corporate, medical and charitable sectors. He became the first news presenter to anchor all the flagship news programmes on Britain’s two main TV channels – the BBC and ITV – and presented special programmes on major events including the start of the Gulf War and the death of the Princess of Wales. “And Finally”, Richard Lindley’s recent book on the history of Independent Television News describes him as “simply one of the best news story film-makers ITN ever employed”. His charitable work includes the Chairmanship of YouthNet UK, a charity he founded in 1995 to create a comprehensive internet site signposting young people to every conceivable opportunity or form of help they might need. It is now used by over 400,000 young people every month. YouthNet has also created the UK’s national volunteering database - www.do-it.org.uk, Martyn is Chairman of the Beacon Fellowship Trust, a charity set up to encourage individual contributions to charitable and social causes and to celebrate and showcase best practice in giving. He has been closely involved with the Hospice movement for over 20 years, and is a Vice-President of the three major national hospice charities – Help The Hospices, Marie Curie Cancer Care and Macmillan Cancer Relief – as well as many individual hospices. He regularly chairs Hospice conferences and Marie Curie’s fund-raising “Brain Games”. Other charity involvement includes : President of United Response, providing homes and work in the community for people with learning disabilities, a Trustee of the Windsor Leadership Trust, helping develop the leaders of tomorrow, and a regular judge for the Dragon Awards, honouring companies based in the City of London for their work in helping the community. He is the author of six books, including “Tears and Smiles – The Hospice Handbook”, the first layman’s guide to the Hospice movement. In 1994, Martyn made the news himself with two controversial and widely-debated speeches arguing for a shift in the agenda of TV news programmes to achieve a fairer balance between the positive and the negative, and report and analyse achievement just as much as failure. He still debates the issues in forums around the world. He holds an honorary degree from the University of Ulster and is a Fellow of the Royal Society of Arts. He was awarded a CBE in 1997.
Susanna Lindvall

Vice President of the European Parkinson’s Disease Association (EPDA) since 2005. Born in Romania 1948, lives in Sweden since 1962 where she graduated as a B.Sc in organic chemistry at the University of Stockholm. She is currently working as an information specialist at a dairy company, Arla Foods. From 1996 - 2002 she was President of the Swedish Parkinson’s Disease Association and since 2002 she has been President of the Swedish Parkinson Foundation and board member of the Arvid Carlson Foundation. Her mother had Parkinson’s disease (PD) and as a result she became involved in questions regarding PD. She is arranging seminars, meetings and conferences in order to improve knowledge about PD both for patients, carers and professionals. She is one of the co writers of a book about PD, used in education of nurses, and she initiated education of PD nurses in Sweden.

Carolin Miltenburger, PhD

is a Director Health Economics & Outcomes with the Berlin office of i3 Innovus. Prior to joining i3 in November 2007, Dr. Miltenburger was the Head of Global Health Economics & Outcomes Research at Schering AG. There, she led the design and execution of HEOR programs and market access studies for a broad range of indications and products with a focus on brain diseases.

Emilio Moreno

obtained his medical degree in the University of Granada (1982) and his PhD in Clinical Pharmacology in 1985. Since then he hold several positions in different Pharmaceutical Companies (Lederle, Boots, Knoll, etc.) where has been involved in the clinical development of antibiotics, NSAID’s, cardiovascular products and antiobesity drugs. Within neurosciences he defended his doctoral thesis about the relevance of monitoring plasma levels of antiepileptic drugs and has participated in the development of drugs for the treatment of depression and schizophrenia. In 2001 he joined Amersham Health (now GE Healthcare) becoming responsible of the Medical Department of Spain and Portugal. He is also European responsible for medical affaires of the dopamine transporter ligand FP-CIT (DaTSCAN®) having been actively involved in phase IV clinical development of this product in the differential diagnosis of uncertain parkinsonian syndromes.
Wolfgang Oertel

heads the Department of Neurology at the Philipps University of Marburg since 1996. Oertel is a neurologist with an international reputation both for his clinical work and experimental studies in the field of movement disorders. He studied at the Free University of Berlin, Germany, and in Newcastle-upon-Tyne, UK. Following 4 years of postgraduate neuroscience training in Berlin and Frankfurt/Main, Germany and at the NIH in Bethesda, Maryland, USA, he completed his residency training at the Department of Neurology, Technical University, Munich, Germany. He won the Parkinson Frost Award. He was tenured as Professor of Neurology, Department of Neurology, University of Munich. His present research topics are basal ganglia disorders, neuroprotection of neurodegenerative disorders and neurological sleep disorders. He is a member of several professional societies including the ENS, EFNS, IBRO, AAN, the Society for Neuroscience, the European Neurological Association, the World Federation of Neurology Research Committee on Extrapyramidal Disease, and the Movement Disorders Society of which he is chairman of the European Section. He is principle investigator in placebo-controlled national and multi-national clinical trials in Movement Disorders and Restless Legs Syndrome and he is involved in the conception and design of studies for EMEA or FDA approval. He initiated and coordinated the European Cooperative Network for Research, Diagnosis and Therapy of Parkinson’s disease, including centers on 11 European nations (2001-2005). He is speaker of the German RLS Patient Register and speaker of the Competence Network on Parkinson’s Disease (CNP), a national network comprising 44 university hospitals and specialized clinics for Parkinson’s Disease across Germany.

Jes Olesen

- MD University of Copenhagen 1967, specialist education in neurology at Copenhagen university hospitals and at Queen Square, London and The New York Hospital, Corness medical center, USA.
- Doctor of Medicine 1974 and Professor of Neurology
- 1985 University of Copenhagen.
- Visiting Professor Harvard Medical School 1999.
- Reviewer and editor of several international scientific journals, president of many international professional organizations and has receiver an honorary doctorate and many other honors and prices.
- Has been leader of a large research group focusing on different aspects of migraine and other headaches including classification, epidemiology, genetics, molecular mechanisms of migraine and brain blood flow. Has published 381 papers in journals with peer review and is the most cited Danish neuroscientist. Has initiated and supervised 16 doctoral theses and 19 PhD theses defended at the University of Copenhagen.
Grezegorz Opala

is a Professor of the Medical University of Silesia in Katowice, Poland and Chairman of the Department of Neurology, Ageing, Degenerative and Cerebrovascular Diseases. He received his medical degree in 1968 from the same university, where he later completed a residency in neurology (1979), as well as a doctoral thesis “Occurrence and clinical significance of excessive elongation and tortuosity of the internal carotid artery” (1978). In 1993 he presented an associate professor (dr. hab.) thesis: “Quantitative and qualitative disorders of carnitine during chronic valproic acid and other anti-epileptic drugs treatment”. His academic development and post-doctoral training was supported by a clinical and research fellowship in neuroradiology at the Department of Neurology of Karol’s University, Prague, Czechoslovakia (1977). Between 1988 and 1991, he worked as a Research Associate in Metabolic Research and Analysis, Inc. and Valley Children’s Hospital, Fresno, Ca, USA. In 1991 and 1993 he was Visiting Professor in the Dept. of Neurology, Veterans Adm. Medical Center, Fresno, California, USA and, in 1998 and 2000 in Rush University, Rush Alzheimer’s Disease Center and Department of Neurological Sciences, Chicago, Illinois, USA. In 2004 he was a visiting scientist in the Mayo Clinic, Department of Neurology, Jacksonville, Florida. In 1998 he organised and subsequently managed the Department of Neurology, Ageing, Degenerative and Cerebrovascular Diseases with Stroke Unit and later the Silesian Stroke Centre and Parkinson’s Disease Centre in the Central University Hospital of the Medical University of Silesia in Katowice.

Werner Poewe

is Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria. He held a Residency in Clinical Neurology and Psychiatry at the University of Innsbruck, Austria, from 1977 to 1984. Then, Professor Poewe was a British Council Research Fellow at University College and Middlesex Hospital Medical School, London. For three years (1986-1989), he was a Senior Lecturer in the Department of Neurology at the University of Innsbruck, Austria. From 1990 through 1994 he served as Professor of Neurology and Acting Director of the Department of Neurology at the Virchow Hospital of the Free University of Berlin. Professor Poewe’s main research interests are in the field of movement disorders with particular emphasis on the clinical pharmacology of Parkinson’s disease and dystonia. He has authored and co-authored more than 400 original articles and reviews in the field of movement disorders. He served as President of the International Movement Disorder Society from 2000 through 2002, as President of the Austrian Society of Neurology from 2002 to 2004 and is the current President of the Austrian Parkinson’s Disease Society.
Pierre Pollak

was born in 1950. He received his Medical Degree specializing in Neurology from the University of Grenoble in 1978, and obtained further qualifications from the Universities of Lyon and Paris. Additional training was done in Paris working with Professors Agid. Pierre Pollak was appointed Full Professor of Neurology at the Joseph Fourier University of Grenoble in 1992. He has been Head of the Neurological Department of Neurology. He is currently chair of the Regional Teaching Program for Neurology and is responsible for the Movement Disorders Unit in the Department of Neurology of the University Hospital of Grenoble. Since 1988, he directs his own research group “Clinical Investigations” within the “Preclinical Neurosciences” laboratory of both the Inserm (the French Agency for Medical Research) and the University of Grenoble. His scientific work has focused on the pathophysiology and experimental therapeutics of movement disorders, particularly Parkinson’s disease. Along with Professor Benabid, he pioneered the treatment of movement disorders by deep brain stimulation of various brain structures, such as the subthalamic nucleus for Parkinson’s disease. Pierre Pollak wrote more than 250 scientific articles in the field of movement disorders and Parkinson’s disease. He is the author of a book dedicated to Parkinson patients and their families “La maladie de Parkinson” (Odile Jacob, Paris, 1993, 2000, 2004). He received the Annemarie Opprecht Foundation Award from the Swiss Parkinson’s Disease Association, the German Neurological Society Price from the Dr Dingebauer Foundation and the Grand Price François Lhermitte from the Medical Research Foundation of the French Academy of Science.
Olivier Rascol

is Professor of Clinical Pharmacology in Toulouse University Hospital since 1993. He obtained his MD in Neurology (Toulouse, 1985) and his PhD in Neurosciences (Paris, 1992). Dr Rascol is running the Toulouse Clinical Research Centre since 1994 and the Toulouse European Space Clinic since 1998. He is also running a Research Group on Motricity in the Research Unit INSERM U825. As a neuropharmacologist, Dr Rascol’s main fields of interest are Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. Dr Rascol is currently running several research programs on neuroprotection, dopamine agonists, dyskinesia and non-dopaminergic antiparkinsonian medications in collaboration with several research centres in the US and in Europe. He is acting in this field as an external advisor for French and European scientific organisations, patients’ associations, drug agencies and international pharmaceutical companies. Dr Rascol is member of several French and American neurological and pharmacological societies. He is the secretary of the Movement Disorders Society and member of the WFN Research Committee on Parkinsonism and Related Disorders. Dr Rascol is working as associate-editor for the Journal Fundamental and Clinical Pharmacology and is a member of the editorial board of the Neurology, the European Journal of Neurology, the Lancet of Neurology and the Journal of Neural Transmission. Dr Rascol has published more than 200 articles in International Scientific journals. He has also been invited to give more than 100 lectures in various European, North and South American and Asian universities or national and international meetings.

Sir Michael Rawlins

has been Chairman of the National Institute for Health & Clinical Excellence (NICE) since its formation in 1999. He has also been Chairman of the Advisory Council on the Misuse of Drugs since 1998. He is an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne. He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006. At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He was a member (1980-1986), Vice-Chairman (1987-1992) and Chairman (1993-1998) of the Committee on Safety of Medicines.
Thomas Stuttaford

is best known as The Times medical columnist. Born in 1931, he was brought up in rural Norfolk where his father and grandfather had been general practitioners. He joined the family practice in 1959 after national service with the Tenth Royal Hussars and medical training at Oxford and in London. From 1970-1974 Dr Stuttaford was Conservative MP for Norwich South, during which time he continued to work as a doctor. Between 1974 and 1995 he worked in the National Health Service as a genito urinary physician, and in private practice as medical advisor to several major companies. Dr Stuttaford has been writing for The Times for twenty one years. He also writes regularly for various magazines, in the past was medical correspondent of Options and Elle, is the medical columnist of Oldie and is a frequent broadcaster.

Eduardo Tolosa

obtained his medical degree from the University of Barcelona and received his neurological training at the University of Minnesota Hospital in Minneapolis. He is Professor of Neurology at the University of Barcelona and Director of the Parkinson Disease and Movement disorder Unit a the University of Barcelona Hospital. He is a founding member and past President of the of the Movement Disorder society and the current chair of the Congress Scientific Program Committee of this society. He is also past president of the European Neurological Society. Professor Tolosa’s research interests are in movement disorders and particularly in issues related to experimental therapeutics, etiology and pathophysiology of various Parkinson syndromes. In the area of experimental therapeutics, he was involved in pioneering studies defining mechanisms underlying levodopa-related motor fluctuations, and his team has been among the first in Europe to evaluate the efficacy of novel surgical strategies for Parkinson’s disease, such as subthalamic nucleus stimulation and its impact upon patients’ cognition and quality of life, subcutaneous dopamine agonist infusions and intraduodenal infusions of levodopa. Other areas of current research include assessment of non-motor symptoms in asymptomatic carriers of PD associated genetic mutations and role of neuroimaging in early detection of Parkinson disease.